HM Payson & Co. purchased a new position in shares of ResMed Inc. (NYSE:RMD) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 2,800 shares of the medical equipment provider’s stock, valued at approximately $202,000.
Several other hedge funds have also made changes to their positions in the stock. BlackRock Inc. boosted its stake in shares of ResMed by 5,439.8% in the first quarter. BlackRock Inc. now owns 13,335,138 shares of the medical equipment provider’s stock worth $959,731,000 after buying an additional 13,094,421 shares during the last quarter. Vanguard Group Inc. raised its stake in ResMed by 4.6% in the first quarter. Vanguard Group Inc. now owns 11,535,707 shares of the medical equipment provider’s stock worth $830,225,000 after buying an additional 508,392 shares during the period. State Street Corp raised its stake in ResMed by 2.1% in the first quarter. State Street Corp now owns 4,598,911 shares of the medical equipment provider’s stock worth $330,983,000 after buying an additional 95,552 shares during the period. FMR LLC raised its stake in ResMed by 1.9% in the first quarter. FMR LLC now owns 4,010,810 shares of the medical equipment provider’s stock worth $288,659,000 after buying an additional 74,389 shares during the period. Finally, Norges Bank purchased a new stake in ResMed during the fourth quarter worth $88,128,000. Institutional investors own 60.74% of the company’s stock.
ResMed Inc. (RMD) opened at 77.59 on Friday. ResMed Inc. has a 12-month low of $56.59 and a 12-month high of $79.44. The stock has a market cap of $11.00 billion, a P/E ratio of 34.03 and a beta of 0.84. The company has a 50 day moving average of $72.98 and a 200-day moving average of $69.45.
ResMed (NYSE:RMD) last released its earnings results on Thursday, April 27th. The medical equipment provider reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.70 by $0.01. The company had revenue of $514.20 million during the quarter, compared to the consensus estimate of $525.84 million. ResMed had a return on equity of 22.53% and a net margin of 15.96%. ResMed’s revenue was up 13.3% compared to the same quarter last year. During the same period in the previous year, the company posted $0.68 EPS. Equities analysts forecast that ResMed Inc. will post $2.80 earnings per share for the current year.
WARNING: This article was first reported by Stock Observer and is the property of of Stock Observer. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.thestockobserver.com/2017/07/16/2800-shares-in-resmed-inc-rmd-acquired-by-hm-payson-co-updated-updated.html.
A number of brokerages have recently commented on RMD. Zacks Investment Research raised shares of ResMed from a “hold” rating to a “buy” rating and set a $87.00 price target on the stock in a report on Thursday, July 6th. BidaskClub raised shares of ResMed from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 17th. BMO Capital Markets reaffirmed a “hold” rating on shares of ResMed in a report on Friday, May 12th. Citigroup Inc. cut shares of ResMed from a “buy” rating to a “neutral” rating in a research report on Friday, April 28th. Finally, Jefferies Group LLC reaffirmed a “sell” rating and issued a $56.00 target price on shares of ResMed in a research report on Friday, April 28th. Four research analysts have rated the stock with a sell rating, four have issued a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. ResMed has a consensus rating of “Hold” and a consensus price target of $64.50.
In other news, CFO Brett Sandercock sold 1,250 shares of the business’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $68.60, for a total transaction of $85,750.00. Following the completion of the transaction, the chief financial officer now directly owns 62,783 shares of the company’s stock, valued at $4,306,913.80. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Richard Sulpizio sold 65,887 shares of the business’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $77.82, for a total value of $5,127,326.34. Following the transaction, the director now directly owns 4,429 shares of the company’s stock, valued at $344,664.78. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 180,260 shares of company stock valued at $13,495,616. 1.97% of the stock is currently owned by corporate insiders.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.